Drugs Made In America Acquisition Corp.
DMAA
$10.54
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 646.52% | 81.99% | -- | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 646.52% | 81.99% | -- | ||
| Operating Income | -646.52% | -81.99% | -- | ||
| Income Before Tax | 176.10% | 1,607.66% | -- | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 176.10% | 1,607.66% | -- | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 176.10% | 1,607.66% | -- | ||
| EBIT | -646.52% | -81.99% | -- | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 118.96% | 485.80% | 2,539.29% | ||
| Normalized Basic EPS | 119.12% | 483.96% | -- | ||
| EPS Diluted | 118.96% | 426.00% | 2,539.29% | ||
| Normalized Diluted EPS | 119.12% | 483.96% | -- | ||
| Average Basic Shares Outstanding | 298.86% | 291.03% | -- | ||
| Average Diluted Shares Outstanding | 298.86% | 291.03% | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||